Vertex at ASN Kidney Week 2026: renal push gathers pace

Vertex Pharmaceuticals showcased its expanding kidney pipeline at ASN Kidney Week 2026, with new data on IgA nephropathy and APOL1-mediated kidney disease. The company highlighted strong clinical results in povetacicept, a B-cell modulator, which showed a 52% reduction in proteinuria at 36 weeks in IgA nephropathy, with a favorable safety profile.

Inaxaplin continued to demonstrate meaningful proteinuria reductions in APOL1-mediated kidney disease, supporting its Phase III program. Vertex executives emphasized the company's transition into a renal-focused entity, aiming for a kidney franchise worth $10 billion across four diseases. The main near-term catalysts for povetacicept are the November 30 FDA decision date and early 2027 interim data from the AMPLITUDE study.

With a market capitalization of $135.6 billion, Vertex remains a prominent biotechnology player, diversifying from its cystic fibrosis franchise.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.